Skip to main content
Terug
NUVL logo

Nuvalent, Inc.

Datakwaliteit: 100%
NUVL
NASDAQ Healthcare Biotechnology
€ 96,43
▲ € 1,66 (1,75%)
Marktkapitalisatie: 7,06B
Dagbereik
€ 94,24 € 97,79
52-Weeksbereik
€ 55,54 € 113,02
Volume
483.457
50D / 200D Gem.
€ 102,59 / € 91,47
Vorige Slotkoers
€ 94,77

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -16,6 0,4
P/B 5,7 2,9
ROE % -36,7 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 137,44 +42.5%
Low: € 120,00 High: € 155,00
Forward WPA
-€ 5,56
Omzet Sch.
14 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 6,16
€ 1,30 – € 12,24
1,3 B 5
FY2029 € 3,26
€ 0,69 – € 6,48
930 M 10
FY2028 -€ 0,93
-€ 4,47 – € 2,94
530 M 12

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -275,21M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-36,70%
ROIC-24,89%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Current Ratio15,27
Interest Coverage0,00

Waardering

P/E Ratio
-16,59
P/B Ratio5,65
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -425,38M
ROE -36,70% ROA -30,11%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -275,21M
ROIC -24,89% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 15,27
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -16,59 P/B Ratio 5,65
P/S Ratio N/A PEG Ratio -0,35
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 7,06B Enterprise Value 6,80B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -425,38M -260,76M -126,22M -81,85M -46,34M
EPS (Diluted) -5,85 -3,93 -2,17 -1,65 -2,13
Gross Profit 0,0 0,0 0,0 0,0 0,0
Operating Income -414,31M -280,37M -149,49M -86,11M -45,82M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,41B 1,14B 732,38M 482,46M 293,82M
Total Liabilities 164,37M 71,96M 31,82M 19,48M 8,79M
Shareholders' Equity 1,25B 1,07B 700,56M 462,98M 285,04M
Total Debt 0,0 0,0 0,0 0,0 0,0
Cash & Equivalents 261,75M 145,69M 335,39M 241,81M 68,53M
Current Assets 1,39B 1,13B 726,49M 477,99M 290,63M
Current Liabilities 91,17M 54,02M 31,82M 19,48M 8,79M